Cargando…
Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a group of devastating genetic diseases characterized by skin and mucosal fragility and formation of blisters, which develop either spontaneously or in response to minor mechanical trauma. There is no definitive therapy for any form of EB. Intermediate junctional EB (JE...
Autores principales: | De Rosa, Laura, Enzo, Elena, Zardi, Giulia, Bodemer, Christine, Magnoni, Cristina, Schneider, Holm, De Luca, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440932/ https://www.ncbi.nlm.nih.gov/pubmed/34539738 http://dx.doi.org/10.3389/fgene.2021.705019 |
Ejemplares similares
-
Dystonin modifiers of junctional epidermolysis bullosa and models of epidermolysis bullosa simplex without dystonia musculorum
por: Sproule, Thomas J., et al.
Publicado: (2023) -
Long-Term Stability and Safety of Transgenic Cultured Epidermal Stem Cells in Gene Therapy of Junctional Epidermolysis Bullosa
por: De Rosa, Laura, et al.
Publicado: (2013) -
Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers
por: Nyström, Alexander, et al.
Publicado: (2021) -
Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa
por: Schwieger‐Briel, Agnes, et al.
Publicado: (2019) -
Digenic Mutations in Junctional Epidermolysis Bullosa in
An Iranian Family
por: Riahi, Kourosh, et al.
Publicado: (2021)